The Cooper Companies, Inc. (NASDAQ:COO) Shares Purchased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP grew its holdings in The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 8.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,558,158 shares of the medical device company's stock after buying an additional 120,330 shares during the quarter. Dimensional Fund Advisors LP owned about 0.78% of Cooper Companies worth $143,234,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of COO. Byrne Asset Management LLC purchased a new position in Cooper Companies in the 4th quarter valued at approximately $33,000. OFI Invest Asset Management purchased a new position in Cooper Companies in the 4th quarter valued at approximately $34,000. New Age Alpha Advisors LLC purchased a new position in Cooper Companies in the 4th quarter valued at approximately $38,000. Covestor Ltd increased its stake in Cooper Companies by 35.5% in the 4th quarter. Covestor Ltd now owns 458 shares of the medical device company's stock valued at $42,000 after purchasing an additional 120 shares in the last quarter. Finally, West Financial Advisors LLC purchased a new position in Cooper Companies in the 4th quarter valued at approximately $49,000. 24.39% of the stock is owned by institutional investors and hedge funds.

Cooper Companies Trading Up 0.5 %

COO traded up $0.38 during midday trading on Tuesday, hitting $82.23. The company's stock had a trading volume of 1,156,744 shares, compared to its average volume of 1,424,626. The company has a current ratio of 1.91, a quick ratio of 1.12 and a debt-to-equity ratio of 0.32. The firm has a market cap of $16.44 billion, a P/E ratio of 42.17, a PEG ratio of 2.25 and a beta of 1.01. The firm has a 50-day moving average price of $82.04 and a two-hundred day moving average price of $92.41. The Cooper Companies, Inc. has a 52-week low of $69.81 and a 52-week high of $112.38.

Cooper Companies (NASDAQ:COO - Get Free Report) last issued its earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.92. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The business had revenue of $964.70 million during the quarter, compared to analysts' expectations of $981.25 million. On average, research analysts anticipate that The Cooper Companies, Inc. will post 3.98 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. BNP Paribas raised Cooper Companies to a "hold" rating in a research report on Thursday, March 13th. JPMorgan Chase & Co. dropped their price objective on Cooper Companies from $120.00 to $110.00 and set an "overweight" rating for the company in a research report on Friday, March 7th. Stifel Nicolaus cut their target price on shares of Cooper Companies from $115.00 to $105.00 and set a "buy" rating for the company in a research note on Friday, March 7th. Needham & Company LLC reissued a "hold" rating on shares of Cooper Companies in a research note on Friday, March 7th. Finally, Piper Sandler reissued an "overweight" rating and issued a $115.00 target price (down previously from $120.00) on shares of Cooper Companies in a research note on Friday, March 7th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $110.25.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.